Cancer Vaccine
Immunologic targeting to obtain minimal response for maximal outcome is reviewed
Published in Vaccine Weekly, July 26th, 2006
According to the review, "Drugs that target extracellular molecules and intracellular pathways remain an area of active research in prostate cancer. Although preclinical data suggest that new drugs can modulate or slow prostate tumor proliferation, responses in man such as disease stabilization or regression are not as dramatic as those seen in preclinical models. Other approaches including carbohydrate and cellular product vaccines, cytokines, and monoclonal antibodies either alone or with radio-pharmaceuticals, are being used to seek...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-07-26)
More Articles from Vaccine Weekly
- Human Papillomavirus Vaccine
Papillomavirus high-grade lesion regression stimulated by MVA E2 recombinant vaccine - Influenza Vaccine
T cell responses are better correlates of flu vaccine protection in the elderly - Meningitis Vaccine
Haemophilus influenzae type b reemerges after DTaP-Hib immunization - Pertussis Vaccine
Alleged vaccine encephalopathy may be caused by gene mutations - Vaccine Development
Tobacco mosaic virus particles were used for display of vaccine antigens - Adenovirus Vaccine
Co-infections of adenovirus species were found in previously vaccinated patients - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
